Design and synthesis of novel pegylated iron chelators with decreased metabolic rate.

BACKGROUND Deferiprone has proved to be a successful iron selective chelator in a range of pathologies. However, its use is limited by rapid Phase II metabolism, necessitating the administration of large doses. In an attempt to modify metabolic rate of this class of compounds, a range of pegylated 3-hydroxypyridin-4-ones has been synthesized. EXPERIMENTAL The synthetic route in which the polyethylene glycol counterparts are introduced to a protected pyran ring involves either a Williamson etherification reaction or direct addition leading to polyethylene glycol-containing precursors. RESULTS & DISCUSSION The introduction of the pegylated substituent was found to lead to a relatively low rate of metabolism for some of the derivatives (6a, 6b, 8a and 8b), offering a possible improvement over deferiprone.

[1]  S. Srichairatanakool,et al.  Characterisation of a novel oral iron chelator: 1‐(N‐Acetyl‐6‐Aminohexyl)‐3‐Hydroxy‐2‐Methylpyridin‐4‐one , 2015, The Journal of pharmacy and pharmacology.

[2]  V. Abbate,et al.  Deferitazole, a new orally active iron chelator. , 2015, Dalton transactions.

[3]  R. Bergeron,et al.  Desferrithiocin: A Search for Clinically Effective Iron Chelators , 2014, Journal of medicinal chemistry.

[4]  E. Kool,et al.  Genetically encoded multispectral labeling of proteins with polyfluorophores on a DNA backbone. , 2013, Journal of the American Chemical Society.

[5]  R. Hider,et al.  A novel fluorescence method for determination of pFe3+. , 2013, The Analyst.

[6]  Xiaole Kong,et al.  Chelating agents for the treatment of systemic iron overload. , 2012, Current medicinal chemistry.

[7]  Vip Viprakasit,et al.  A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. , 2012, Blood.

[8]  F. Veronese,et al.  The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.

[9]  Massimo Midiri,et al.  Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and Function Comparison Determined by Quantitative Magnetic Resonance Imaging Early Release Paper Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and , 2022 .

[10]  D. van der Helm,et al.  Amido-3-hydroxypyridin-4-ones as iron(III) ligands. , 2010, Chemistry.

[11]  H. Bobby Gaspar,et al.  Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID) , 2009, Biologics : targets & therapy.

[12]  U. Schaible,et al.  Targeting the lysosome: fluorescent iron(III) chelators to selectively monitor endosomal/lysosomal labile iron pools. , 2008, Journal of medicinal chemistry.

[13]  T. Pivetta,et al.  Potentiometric, spectrophotometric and calorimetric study on iron(III) and copper(II) complexes with 1,2-dimethyl-3-hydroxy-4-pyridinone. , 2008, Journal of inorganic biochemistry.

[14]  Gil Y. Melmed,et al.  Certolizumab pegol , 2022, Nature Reviews Drug Discovery.

[15]  T. Ganz,et al.  Liver iron concentrations and urinary hepcidin in beta-thalassemia. , 2007, Haematologica.

[16]  A. Cnaan,et al.  Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. , 2006, Blood.

[17]  J. Porter,et al.  Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. , 2002, Best practice & research. Clinical haematology.

[18]  J. Balfour,et al.  Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. , 1999, Drugs.

[19]  P. Gans,et al.  Hyperquad simulation and speciation (HySS): a utility program for the investigation of equilibria involving soluble and partially soluble species , 1999 .

[20]  P. Gans,et al.  Determination of equilibrium constants from spectrophometric data obtained from solutions of known pH : The program pHab , 1999 .

[21]  P. Gans,et al.  Investigation of equilibria in solution. Determination of equilibrium constants with the HYPERQUAD suite of programs. , 1996, Talanta.

[22]  P. Dobbin,et al.  Synthesis, Physicochemical Properties, and Biological Evaluation of N- Substituted 2-Alkyl-3-hydroxy-4(1H)-pyridinones: Orally Active Iron Chelators with Clinical Potential. , 1994 .

[23]  D. van der Helm,et al.  Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. , 1993, Journal of medicinal chemistry.

[24]  P. Dobbin,et al.  Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. , 1992, Drug metabolism and disposition: the biological fate of chemicals.